Drug Delivery: Faculty and Staff
The Ainslie Lab focuses on modulation of immune responses to prevent and treat cancer, infectious and autoimmune diseases.
The Fenton Lab seeks to develop synthetic drug delivery platforms using RNA therapeutics.
The Hingtgen Lab develops engineered stem cell-based therapies for brain cancers and other tumors.
The Kabanov Lab focuses on nanomedicines for delivery of small drugs, nucleic acids and polypeptides to treat cancers and diseases of the central nervous system.
The Lai Lab focuses on infectious diseases at mucosal surfaces, targeted drug delivery and nanoparticle-immune interactions.
The Nguyen Lab focuses on developing genetically encoded and genetically engineered biotherapeutics for the treatment of cancer, myocardial infarction, colitis, and other diseases.
Learn more about Pharmacoengineering and Molecular Pharmaceutics
Dr. Benhabbour’s research focuses on the development of novel delivery platforms and polymer-based devices that can treat or prevent disease.
Dr. Dayton is the William R. Kenan Distinguished Professor of Biomedical Engineering, and Chair of the Joint UNC-NCSU Department of Biomedical Engineering.
Dr. Dotti is a research professor of microbiology and immunology at UNC and Director of the Lineberger Comprehensive Cancer Center Immunotherapy Program.
Dr. Han specializes in gene and drug delivery for retinal diseases.
Dr. Lin’s is the Dixie Lee Boney Soo Distinguished Professor of Neurological Medicine and Director of the Biomedical Research Imaging Center (BRIC) at the University of North Carolina at Chapel Hill.
Dr. Eric Bachelder focuses on the development of biomaterials for the treatment of diseases associated with the immune system.
The main focus of Dr. Elena Batrakova’s research is to develop a CNS delivery system for neurodegenerative disorders, such as Parkinson’s and Alzheimer’s diseases.
Dr. Jillian Perry leverages her knowledge of polymer chemistry, biomaterials, and drug delivery to develop novel drug delivery carriers for the treatment of cancer and infectious diseases.
Lindsay Androski, JD, MBA, CFA is Founder, President and CEO of Roivant Social Ventures, a social impact organization that makes early stage investments & incubates biotechs, with an emphasis on cell & gene therapies.
Dr. Edward Bahnson’s research program focuses on the study of arterial disease, and developing new therapies to treat cardiovascular disease.
Dr. Ken Brouwer is Vice President of Technology, ADME-TOX at BioIVT, and has successfully lead and directed large international multidisciplinary project teams to support the product development of high priority development candidates.
Dr. David Zaharoff’s Lab focuses on the development of translatable immunotherapy delivery platforms. They use a multidisciplinary approach to engineer biomaterials-based and technology-driven localized immunotherapy strategies.
Dr. Geoffrey Hird is the Chief Technology Officer at Glycomine and has more than 20 years of experience in all stages of pharmaceutical product development having held positions at Eisai, GSK, and Liquidia Technologies.
Prof. Dr. Kazunori Kataoka is the Center Director of Innovation Center of NanoMedicine (iCONM), which is operated by Kawasaki Institute of Industrial Promotion. He is also an Emeritus Professor of the University of Tokyo.
Dr. Lu is Director of the McColl-Lockwood Laboratory for Muscular Dystrophy Research at Atrium Health. His main research interests are experimental therapies for limb girdle muscular dystrophies and is considered one of the world’s leading experts studying LGMD2i.
Dr. Lesley Marson was most recently Director of Sexual Health Research at Urogenix Inc. Prior to that she held the position of Professor in the Urology Division of the Department of Surgery, University of North Carolina, Chapel Hill.
Dr. Hickey directs UNC Catalyst for Rare Disease, and is an RTI distinguished fellow in and program director for inhaled therapeutics.
Dr. Jay’s research projects have centered on the interface between the pharmaceutical and nuclear sciences, involving the application of pharmaceutical approaches to solve problems related to nuclear imaging and therapy.
Dr. Juliano is one of the founders of Initos Pharmaceuticals, is an expert on oligonucleotide-based therapeutics, and is the originator of the OEC technology.
Dr. Xiao’s work on muscular dystrophy, especially Duchenne muscular dystrophy, has received international recognition.
Dr. Huang’s research has been in the area of gene therapy and targeted drug delivery. He pioneered the liposome non-viral vector and designed and manufactured the cationic lipid vector for the first non-viral clinical trial in 1992.